Literature DB >> 15388216

Are 1 or 2 dangerous? Clozapine and olanzapine exposure in toddlers.

David C Wong1, Liesl A Curtis.   

Abstract

Clozapine (Clozaril) and olanzapine (Zyprexa) are two relatively new atypical antipsychotics that are structurally and pharmacologically related. There are currently no therapeutic indications for these pharmaceuticals in infants and toddlers.Presumably, as the usage of these medications in adults increases, the frequency of unintentional pediatric ingestions will increase. In 2001 the annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System included a separate subcategory for atypical antipsychotics under the heading of sedatives/hypnotics/antipsychotics. The toxidrome resulting from these drugs is predominately central nervous system depression and anticholinergic effects. Although the desirable lack of extrapyramidal symptoms in adults results in their greatest clinical utility, several reports of toxic ingestions in small children are noteworthy for having extrapyramidal manifestations. We review here the available reported clinical experience with toxic doses of these medications that in small children may amount to as little as a single tablet. Although such doses may be lethal, supportive care and gastrointestinal decontamination in this population will generally lead to a good outcome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15388216     DOI: 10.1016/j.jemermed.2004.06.004

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  1 in total

1.  Atypical antipsychotic poisoning in young children: a multicentre analysis of poisons centres data.

Authors:  Marianne Meli; Christine Rauber-Lüthy; Petra Hoffmann-Walbeck; Hans-Jürgen Reinecke; Dagmar Prasa; Uwe Stedtler; Elke Färber; Dieter Genser; Hugo Kupferschmidt; Gerd A Kullak-Ublick; Alessandro Ceschi
Journal:  Eur J Pediatr       Date:  2013-12-27       Impact factor: 3.183

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.